tiprankstipranks
New Share Price & Shareholder Rights Risk for Adaptimmune Therapeutics Plc. – What’s the Latest?
PremiumCompany AnnouncementsNew Share Price & Shareholder Rights Risk for Adaptimmune Therapeutics Plc. – What’s the Latest?
2M ago
Adaptimmune upgraded to Buy from Hold at JonesResearch
PremiumThe Fly
Adaptimmune upgraded to Buy from Hold at JonesResearch
2M ago
Adaptimmune management to meet with Truist
PremiumThe Fly
Adaptimmune management to meet with Truist
2M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
3M ago
Adaptimmune says afami-cel BLA accepted for FDA priority review
PremiumThe Fly
Adaptimmune says afami-cel BLA accepted for FDA priority review
3M ago
Adaptimmune’s T-Cell Therapy Priority Review by FDA
PremiumCompany Announcements
Adaptimmune’s T-Cell Therapy Priority Review by FDA
3M ago
ADAP Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsADAP Upcoming Earnings Report: What to Expect?
12M ago
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
PremiumThe Fly
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
1y ago
Adaptimmune taking back PRAME and NY-ESO target programs from GSK
PremiumThe Fly
Adaptimmune taking back PRAME and NY-ESO target programs from GSK
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100